AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Hersima 150mg Injection

Prescription Icon
Prescription Required

Marketer

Alkem Laboratories Ltd

Salt Composition

Trastuzumab (150mg)

Overview Hersima 150mg Injection

Oncaspar, a 150mg injectable solution, treats breast and gastric cancers. Its mechanism involves targeting and destroying cancerous cells by suppressing HER2, the human epidermal growth factor receptor 2 protein. Administration is strictly via injection by a qualified healthcare professional. Dosage and frequency are determined individually by your physician, varying based on your condition and potentially adjusted over time. Adhere precisely to your doctor's instructions; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic benefits might not be immediately apparent; noticeable effects may take weeks or months. Discontinue only under medical supervision. Common side effects encompass nausea, headache, skin rashes, sleep disturbances, and infections. This medication can lower blood cell counts (red and white blood cells), increasing infection risk. Regular blood tests to monitor blood cell levels, along with cardiac, hepatic, and uric acid levels, are mandatory. Report any shortness of breath, cough, chills, or limb swelling immediately. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and lactation; reliable contraception for both partners is crucial throughout treatment.

Uses of Hersima 150mg Injection

Cancers affecting the breast and stomach.

Major Benefits of Hersima 150mg Injection:

This medication will be administered by your healthcare provider; self-medication is strictly prohibited.

Common Side effects of Hersima 150mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Hersima 150mg Injection:

This medication will be administered by your physician or their qualified staff. Self-medication is strictly prohibited.

How Hersima 150mg Injection works:

Hersima 150mg Injection, a genetically engineered IgG1 monoclonal antibody, targets HER2, the human epidermal growth factor receptor 2 protein. Overexpression of HER2 drives excessive growth in breast and gastric cancers. The injection neutralizes HER2, leading to cancer cell death and the disruption of multiple downstream signaling pathways crucial for tumor development.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of Hersima 150mg Injection and alcohol may result in increased sleepiness.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Hersima 150mg Injection during pregnancy is contraindicated due to established harm to the fetus. Exceptions may exist in critical circumstances where the potential benefits outweigh the known risks, at the physician's sole discretion. Physician consultation is mandatory.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administration of Hersima 150mg Injection while breastfeeding is likely inadvisable. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

Hersima 150mg Injection's effect on driving ability is undetermined. Refrain from driving if you develop symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

The use of Hersima 150mg Injection in individuals with kidney impairment appears to pose minimal risk. Existing evidence indicates dose modification may be unnecessary, however, physician consultation is advised.

LiverLiverCONSULT YOUR DOCTOR

Insufficient data exists regarding Hersima 150mg Injection's use in individuals with hepatic impairment. Physician consultation is advised.

What if you forget to take Hersima 150mg Injection :

Omit a Hersima 150mg Injection dose? Seek medical advice immediately.

Facts to Know About Hersima 150mg Injection

LabelValue
Type of Compound Single-clone antibody
Addictive None.
Treatment Category Cancer-fighting drugs
Mechanism of Action Anti-HER2/neu (ErbB2) monoclonal antibody therapy

FAQs on Hersima 150mg Injection

Hersima 150mg Injection may cause several adverse reactions, including throat irritation, pyrexia, rigors, profound fatigue, pallor, epistaxis, and atypical bleeding or bruising. Patients may also present with abdominal discomfort, convulsions, visual or auditory disturbances, myalgia, and muscle spasms. Additionally, nausea and emesis, anorexia, lassitude, tachycardia, altered urine color, oliguria, dysuria, urinary pain, and other signs of infection may occur. Seek immediate medical attention if any of these symptoms develop.
Females capable of becoming pregnant must employ reliable birth control methods throughout their Hersima 150mg Injection treatment and for seven months following its conclusion. Pregnancy planning may commence seven months post-treatment with Hersima 150mg Injection.
Individuals diagnosed with early-stage breast cancer should receive Hersima 150mg Injection for a duration of one year, or until disease progression, whichever event precedes the other. Treatment should not continue past one year in early breast cancer cases.
Hersima 150mg Injection does not necessitate prior fasting. Administration must be overseen by a physician specializing in cancer chemotherapy and performed exclusively by qualified medical personnel.
Hersima 150mg Injection is available in two distinct delivery methods: intravenous infusion (into a vein) and subcutaneous injection (under the skin). Careful review of the product labeling is crucial to confirm accurate administration per prescription. The intravenous formulation is exclusively for intravenous infusion and must not be administered subcutaneously. Your physician may elect to change your Hersima 150mg Injection treatment between intravenous and subcutaneous routes if deemed clinically suitable.
Hersima 150mg Injection is contraindicated in individuals with HER2-negative cancers. This monoclonal antibody selectively targets the human epidermal growth factor receptor 2 (HER2) protein, abundant on the surface of certain cancer cells. By binding to HER2, Hersima 150mg Injection inhibits cancer cell proliferation and metastasis. Consequently, its therapeutic efficacy is limited to patients exhibiting HER2 positivity; it offers no benefit to those lacking HER2 expression.
The use of Hersima 150mg Injection concurrently with anthracycline-based anticancer drugs, such as doxorubicin, carries a potential risk of cardiac complications. Therefore, a cardiac assessment is mandatory both prior to and throughout the course of treatment.
Cardiac evaluations are necessary at treatment initiation. These evaluations should recur every three months throughout treatment and every six months following treatment cessation, continuing for two years post-final Hersima 150mg Injection. Patients with pre-existing cardiac conditions require assessment every twelve weeks.
Hersima 150mg Injection
15,704
MRP 19,133
17% off